Skip to main content
Veeral Sheth, MD, Ophthalmology, Oak Forest, IL

Veeral Sheth MD MBA, FACS

Glaucoma Related, Retinal Disease, Uveitis


Physician and Surgeon Clinical Assistant Professor, University of Illinois at Chicago

Join to view full profile
  • 6320 159th StSte AOak Forest, IL 60452

  • Phone+1 708-687-2222

  • Fax+1 708-687-3829

Dr. Sheth is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Northwestern University (Kellogg)
    Northwestern University (Kellogg)MBA, 2012 - 2014
  • University of Chicago
    University of ChicagoFellowship, Surgical Retina and Vitreous, 2010
  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Ophthalmology, 2004 - 2008
  • West Suburban Medical Center
    West Suburban Medical CenterInternship, Transitional Year, 2004 - 2005
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 2004

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2008 - 2029
  • Ophthalmology
    American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification eClinicalWorks, eClinicalWorks, LLC, 2011, 2014-2016
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2014-2016
  • CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2011, 2014-2016

Clinical Trials

Publications & Presentations

PubMed

Books/Book Chapters

Press Mentions

  • Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)
    Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)June 9th, 2025
  • Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DME
    Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEOctober 21st, 2024
  • EyeSouth Partners Expands Clinical Research Division - Healthcare and Medical News for Atlanta Physicians
    EyeSouth Partners Expands Clinical Research Division - Healthcare and Medical News for Atlanta PhysiciansJuly 9th, 2024

Professional Memberships

Other Languages

  • Spanish, Gujarati

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: